vs

Side-by-side financial comparison of HARROW, INC. (HROW) and STEM, INC. (STEM). Click either name above to swap in a different company.

HARROW, INC. is the larger business by last-quarter revenue ($89.1M vs $47.1M, roughly 1.9× STEM, INC.). HARROW, INC. runs the higher net margin — 7.4% vs -33.9%, a 41.3% gap on every dollar of revenue. On growth, HARROW, INC. posted the faster year-over-year revenue change (33.3% vs -15.6%). Over the past eight quarters, HARROW, INC.'s revenue compounded faster (60.5% CAGR vs 36.1%).

Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee.

StemCells, Inc. is a public biopharmaceutical company headquartered in Newark, California, that is developing purified human neural stem cells (HuCNS-SCs) in the hopes of treating central nervous system disorders and paralysis. StemCells' HuCNS-SCs have the ability to differentiate into the three main types of cells found in the central nervous system: neurons, astrocytes and oligodendrocytes.

HROW vs STEM — Head-to-Head

Bigger by revenue
HROW
HROW
1.9× larger
HROW
$89.1M
$47.1M
STEM
Growing faster (revenue YoY)
HROW
HROW
+48.9% gap
HROW
33.3%
-15.6%
STEM
Higher net margin
HROW
HROW
41.3% more per $
HROW
7.4%
-33.9%
STEM
Faster 2-yr revenue CAGR
HROW
HROW
Annualised
HROW
60.5%
36.1%
STEM

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HROW
HROW
STEM
STEM
Revenue
$89.1M
$47.1M
Net Profit
$6.6M
$-16.0M
Gross Margin
79.3%
48.9%
Operating Margin
17.5%
-17.7%
Net Margin
7.4%
-33.9%
Revenue YoY
33.3%
-15.6%
Net Profit YoY
-2.2%
68.8%
EPS (diluted)
$0.20
$-4.40

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HROW
HROW
STEM
STEM
Q4 25
$89.1M
$47.1M
Q3 25
$71.6M
$38.2M
Q2 25
$63.7M
$38.4M
Q1 25
$47.8M
$32.5M
Q4 24
$66.8M
$55.8M
Q3 24
$49.3M
$29.3M
Q2 24
$48.9M
$34.0M
Q1 24
$34.6M
$25.5M
Net Profit
HROW
HROW
STEM
STEM
Q4 25
$6.6M
$-16.0M
Q3 25
$1.0M
$-23.8M
Q2 25
$5.0M
$202.5M
Q1 25
$-17.8M
$-25.0M
Q4 24
$6.8M
$-51.1M
Q3 24
$-4.2M
$-148.3M
Q2 24
$-6.5M
$-582.3M
Q1 24
$-13.6M
$-72.3M
Gross Margin
HROW
HROW
STEM
STEM
Q4 25
79.3%
48.9%
Q3 25
75.3%
35.5%
Q2 25
74.5%
33.4%
Q1 25
67.5%
32.4%
Q4 24
78.8%
-4.4%
Q3 24
75.6%
21.2%
Q2 24
74.4%
27.6%
Q1 24
69.5%
-95.0%
Operating Margin
HROW
HROW
STEM
STEM
Q4 25
17.5%
-17.7%
Q3 25
20.6%
-33.6%
Q2 25
17.9%
-34.8%
Q1 25
-23.5%
-65.0%
Q4 24
19.3%
-84.4%
Q3 24
2.7%
-493.2%
Q2 24
3.1%
-1705.5%
Q1 24
-20.0%
-267.0%
Net Margin
HROW
HROW
STEM
STEM
Q4 25
7.4%
-33.9%
Q3 25
1.4%
-62.2%
Q2 25
7.8%
527.8%
Q1 25
-37.2%
-76.9%
Q4 24
10.1%
-91.6%
Q3 24
-8.6%
-506.3%
Q2 24
-13.2%
-1712.6%
Q1 24
-39.2%
-283.9%
EPS (diluted)
HROW
HROW
STEM
STEM
Q4 25
$0.20
$-4.40
Q3 25
$0.03
$-2.84
Q2 25
$0.13
$-1.79
Q1 25
$-0.50
$-0.15
Q4 24
$0.19
$-15.29
Q3 24
$-0.12
$-18.24
Q2 24
$-0.18
$-71.81
Q1 24
$-0.38
$-0.46

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HROW
HROW
STEM
STEM
Cash + ST InvestmentsLiquidity on hand
$72.9M
$48.9M
Total DebtLower is stronger
$250.0M
Stockholders' EquityBook value
$52.4M
$-249.4M
Total Assets
$399.5M
$308.9M
Debt / EquityLower = less leverage
4.77×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HROW
HROW
STEM
STEM
Q4 25
$72.9M
$48.9M
Q3 25
$74.3M
$43.1M
Q2 25
$53.0M
$40.8M
Q1 25
$66.7M
$58.6M
Q4 24
$47.2M
$56.3M
Q3 24
$72.6M
$75.4M
Q2 24
$71.0M
$89.6M
Q1 24
$76.0M
$112.8M
Total Debt
HROW
HROW
STEM
STEM
Q4 25
$250.0M
Q3 25
$347.2M
Q2 25
$250.6M
Q1 25
$256.9M
Q4 24
$262.7M
Q3 24
$230.7M
Q2 24
$236.3M
Q1 24
$243.4M
Stockholders' Equity
HROW
HROW
STEM
STEM
Q4 25
$52.4M
$-249.4M
Q3 25
$47.0M
$-235.7M
Q2 25
$49.7M
$-214.1M
Q1 25
$56.5M
$-417.5M
Q4 24
$69.7M
$-398.4M
Q3 24
$58.0M
$-344.1M
Q2 24
$58.5M
$-203.2M
Q1 24
$60.6M
$371.6M
Total Assets
HROW
HROW
STEM
STEM
Q4 25
$399.5M
$308.9M
Q3 25
$363.1M
$362.6M
Q2 25
$345.0M
$379.2M
Q1 25
$364.2M
$405.1M
Q4 24
$389.0M
$437.4M
Q3 24
$351.5M
$537.8M
Q2 24
$306.6M
$691.5M
Q1 24
$295.5M
$1.3B
Debt / Equity
HROW
HROW
STEM
STEM
Q4 25
4.77×
Q3 25
7.39×
Q2 25
5.05×
Q1 25
4.55×
Q4 24
3.77×
Q3 24
3.98×
Q2 24
4.04×
Q1 24
4.02×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HROW
HROW
STEM
STEM
Operating Cash FlowLast quarter
$8.4M
$8.2M
Free Cash FlowOCF − Capex
$8.1M
FCF MarginFCF / Revenue
9.1%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
1.27×
TTM Free Cash FlowTrailing 4 quarters
$43.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HROW
HROW
STEM
STEM
Q4 25
$8.4M
$8.2M
Q3 25
$16.6M
$11.4M
Q2 25
$-803.0K
$-21.3M
Q1 25
$19.7M
$8.5M
Q4 24
$-17.8M
$-14.7M
Q3 24
$3.0M
$-9.4M
Q2 24
$-2.7M
$-11.9M
Q1 24
$-4.6M
$-621.0K
Free Cash Flow
HROW
HROW
STEM
STEM
Q4 25
$8.1M
Q3 25
$16.4M
Q2 25
$-969.0K
Q1 25
$19.5M
Q4 24
$-18.3M
Q3 24
$2.3M
Q2 24
$-3.1M
Q1 24
$-4.7M
FCF Margin
HROW
HROW
STEM
STEM
Q4 25
9.1%
Q3 25
22.9%
Q2 25
-1.5%
Q1 25
40.8%
Q4 24
-27.4%
Q3 24
4.8%
Q2 24
-6.3%
Q1 24
-13.6%
Capex Intensity
HROW
HROW
STEM
STEM
Q4 25
0.4%
Q3 25
0.3%
Q2 25
0.3%
Q1 25
0.4%
Q4 24
0.8%
Q3 24
1.2%
Q2 24
0.7%
Q1 24
0.3%
Cash Conversion
HROW
HROW
STEM
STEM
Q4 25
1.27×
Q3 25
16.26×
Q2 25
-0.16×
-0.11×
Q1 25
Q4 24
-2.62×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons